Argenx CEO Tim Van Hauwermeiren is stepping down in May and will be succeeded by Karen Massey, the Belgian drugmaker's COO.

Neuralink, a leader in the fledgling field of brain implants, is hurting the industry's efforts to develop useful medical ...

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the first quarter: Alumis: Top-line ...

ATLATL, one of China’s leading biotech incubators, is seeking to bridge East-West innovation and tap into China's rapidly ...

When Americans make decisions — like whether to pack an umbrella or prepare for a hurricane — they rely on clear, timely, and ...

A new year always brings new challenges, and there will be many challenges facing the pharmaceutical industry and policymakers in 2026 as Americans continue to clamor for affordable medicines that ...

In 2026, disability advocates want expanded access to primary and emergency care — and influence new debates around genetic ...

Babies who don’t get their first round of vaccines on time at 2 months of age are much less likely to get vaccinated against ...

It has been a tough year for medicine. The U.S. research enterprise has been scrambled by a series of political decisions ...

NIH Director Jay Bhattacharya told a podcaster that DEI-related grants restored under a court order won't be renewed in 2026 ...

As a public health scientist, I have learned that firm prescriptions rarely capture life’s complexity,” Robert M. Kaplan ...

What to watch out for in 2026, as the health care industry gears up for a battle over how clinical AI should get paid for.